Arimoclomol for the Treatment of Niemann-pick Disease Type C In a Real-world Setting: Long-term Data from an Expanded Access Program in the United States
Monday, February 3, 2025 BiopharmaWatch Research 1 min read
Key Takeaway: The article discusses long-term data from an expanded access program for Arimoclomol, a treatment for Niemann-pick Disease Type C. Presented at the 21st Annual WORLDSymposium, the findings indicate positive outcomes in real-world settings. This data may enhance understanding of Arimoclomol's efficacy over time.
Price reaction · baseline $7.84 (2025-01-31 close) · hit pre-market · 6 other ZVRA headline(s) in the window, move may be shared
day 0 close · peak
-2.4%
Market Sentiment Analysis
POSITIVE FACTORS
Long-term data supports the efficacy of Arimoclomol.
Expanded access program shows promise for Niemann-pick Disease Type C.
Positive outcomes reported in real-world settings.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+71%
120-day peak, hindsight
Typical move
10.7%
average across 6 past catalysts
Lead asset
KP415
Phase 3 · ADHD
Full Press Release Details
< Medical Publications and Presentations
Arimoclomol for the Treatment of Niemann-pick Disease Type C In a Real-world Setting: Long-term Data from an Expanded Access Program in the United States
21st Annual WORLDSymposium - 02/05/2025
Download PDF
Download PDF
Frequently Asked Questions
What is Arimoclomol used for?
Arimoclomol is used for the treatment of Niemann-pick Disease Type C.
What does the long-term data indicate?
The long-term data suggests positive outcomes for Arimoclomol in real-world settings.
Where was the data presented?
The data was presented at the 21st Annual WORLDSymposium.
What type of program provided the data?
The data comes from an expanded access program in the United States.